M M. Colorado

Santander, CB, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Journal: Haematologica

Published: July 07, 2026

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

Journal: American journal of hematology

Published: June 23, 2026

Feasibility and Interim Safety and Efficacy Analysis of a Fast Automated Production of Prophylactic Cytomegalovirus-Specific Cytotoxic T Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation.

Feasibility and Interim Safety and Efficacy Analysis of a Fast Automated Production of Prophylactic Cytomegalovirus-Specific Cytotoxic T Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: May 30, 2026

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Journal: Haematologica

Published: March 10, 2026

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Journal: Blood

Published: February 05, 2026

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

Journal: American journal of hematology

Published: February 05, 2026

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

Peripheral blood stem cells versus bone marrow graft for non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.

Peripheral blood stem cells versus bone marrow graft for non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT.

Journal: Bone marrow transplantation

Published: October 27, 2025

FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML Patients.

FLAG-IDA LITE: A Reasonable Induction Regimen for Elderly AML Patients.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 22, 2025

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 13, 2025

CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry.

CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry.

Journal: Hematological oncology

Published: September 29, 2025

Real-world experience of treosulfan in allogeneic stem cell transplantation in adult patients with myeloid malignancies. Spanish Group of SCT and Cell Therapy (GETH-TC).

Real-world experience of treosulfan in allogeneic stem cell transplantation in adult patients with myeloid malignancies. Spanish Group of SCT and Cell Therapy (GETH-TC).

Journal: Bone marrow transplantation

Published: September 29, 2025

Showing 1-12 of 40

Last Updated: 09/26/2026